Infensa Bioscience
June 16, 2025
Company Presentation
Cardiovascular
Infensa Bioscience: Pioneering Cardioprotection and Neuroprotection Through ASIC1a Inhibition
Infensa Bioscience is a private biotech company advancing IB409, a potent ASIC1a inhibitor targeting cardiovascular and ischemic diseases. ASIC1a is a well-validated ion channel linked to ischemia-induced tissue damage. IB409 has demonstrated robust efficacy at low doses in preclinical models of heart attack, transplant, stroke, and kidney ischemia.
With no approved cardioprotective or neuroprotective therapies on the market, IB409 addresses a major unmet need. IND studies are complete, and Phase 1 trials begin Q3 2025.
At BIO2025, we aim to attract partners and investors aligned with our transition to Phase 2 trials. Our experienced leadership, strong science, and scalable opportunity make Infensa a compelling partner in redefining care for the world’s leading causes of death.
Company HQ City:
Woolloongabba
Company HQ State:
Queensland
Company HQ Country:
Australia
Year Founded:
2021
Lead Product in Development:
Acid-sensing ion channel 1a (ASIC1a) inhibitor, for myocardial infarction (heart attack) and stroke.
CEO
Mark Smythe
Development Phase of Lead Product
Phase I
When you expect your next catalyst update?
November 2025 First Human Dose
What is your next catalyst (value inflection) update?
November 2025 First Human Dose
Primary Speaker
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}